Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications

Biological Psychiatry

Volumn 84, Issue 3, 2018, Pages 180-192

  Caprioli, Daniele ^a   Justinova, Zuzana ^b   Venniro, Marco ^b   Shaham, Yavin ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction; Glutamate; PAMs and NAMs; Positive and negative allosteric modulators; Relapse; Self administration

Indexed keywords

A 841720; AMINO ACID RECEPTOR AFFECTING AGENT; AZD 8529; BINA; CDPPB; CPCCOET; EMQMCM; FENOBAM SULFATE; JNJ 16259685; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR NEGATIVE ALLOSTERIC MODULATOR; METABOTROPIC RECEPTOR POSITIVE ALLOSTERIC MODULATOR; MFZ 10 7; N,N' DIBENZHYDRYLETHYLENEDIAMINE; SYN 119; UNCLASSIFIED DRUG; VU 0463841;

DRUG CRAVING; DRUG MECHANISM; DRUG SEEKING BEHAVIOR; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; ALLOSTERISM; ANIMAL; CRAVING; DISEASE MODEL; DRUG DEPENDENCE; DRUG EFFECT; DRUG SELF ADMINISTRATION; HUMAN; METABOLISM;

ALLOSTERIC REGULATION; ANIMALS; CRAVING; DISEASE MODELS, ANIMAL; DRUG-SEEKING BEHAVIOR; EXCITATORY AMINO ACID AGENTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 85033436099     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2017.08.018     Document Type: Review

References (150)

1. Karler, R., Calder, L.D., Chaudhry, I.A., Turkanis, S.A., Blockade of “reverse tolerance” to cocaine and amphetamine by MK-801. Life Sci 45 (1989), 599–606.
2. Stewart, J., Druhan, J.P., Development of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the non-competitve NMDA receptor antagonist, MK-801. Psychopharmacology 110 (1993), 125–132.
3. Wolf, M.E., Khansa, M.R., Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res 562 (1991), 164–168.
4. Kalivas, P.W., Alesdatter, J.E., Involvement of N-methyl-D-aspartate receptor stimulation in the ventral tegmental area and amygdala in behavioral sensitization to cocaine. J Pharmacol Exp Ther 267 (1993), 486–495.
5. Wolf, M.E., The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54 (1998), 679–720.
6. Vanderschuren, L.J., Kalivas, P.W., Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies. Psychopharmacology (Berl) 151 (2000), 99–120.
7. Pierce, R.C., Kalivas, P.W., A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25 (1997), 192–216.
8. Kalivas, P.W., McFarland, K., Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology 168 (2003), 44–56.
9. Park, W.K., Bari, A.A., Jey, A.R., Anderson, S.M., Spealman, R.D., Rowlett, J.K., et al. Cocaine administered into the medial preforntal cortex reinstates cocaine-seeking behavior by increasing AMPA receptor-mediated glutamate transmission in the nucleus accumbens. J Neurosci 22 (2002), 2916–2925.
10. Cornish, J.L., Duffy, P., Kalivas, P.W., A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behavior. Neuroscience 93 (1999), 1359–1367.
11. Cornish, J.L., Kalivas, P.W., Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. J Neurosci, 20, 2000, RC89.
12. McFarland, K., Kalivas, P.W., The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 21 (2001), 8655–8663.
13. McFarland, K., Lapish, C.C., Kalivas, P.W., Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 23 (2003), 3531–3537.
14. Shaham, Y., Shalev, U., Lu, L., De Wit, H., Stewart, J., The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology 168 (2003), 3–20.
15. Di Ciano, P., Everitt, B.J., Dissociable effects of antagonism of NMDA and AMPA/KA receptors in the nucleus accumbens core and shell on cocaine-seeking behavior. Neuropsychopharmacology 25 (2001), 341–360.
16. Di Ciano, P., Everitt, B.J., Direct interactions between the basolateral amygdala and nucleus accumbens core underlie cocaine-seeking behavior by rats. J Neurosci 24 (2004), 7167–7173.
17. White, F.J., Kalivas, P.W., Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51 (1998), 141–153.
18. Nestler, E.J., Molecular neurobiology of addiction. Am J Addict 10 (2001), 201–217.
19. Bonci, A., Williams, J.T., A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. Neuron 16 (1996), 631–639.
20. Ungless, M.A., Whistler, J.L., Malenka, R.C., Bonci, A., Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 411 (2001), 583–587.
21. Zhang, X.F., Hu, X.T., White, F.J., Wolf, M.E., Increased responsiveness of ventral tegmental area dopamine neurons to glutamate after repeated administration of cocaine or amphetamine is transient and selectively involves AMPA receptors. J Pharmacol Exp Ther 281 (1997), 699–706.
22. Mansvelder, H.D., McGehee, D.S., Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27 (2000), 349–357.
23. Kenny, P.J., Markou, A., The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 25 (2004), 265–272.
24. Liechti, M.E., Markou, A., Role of the glutamatergic system in nicotine dependence: Implications for the discovery and development of new pharmacological smoking cessation therapies. CNS Drugs 22 (2008), 705–724.
25. Kalivas, P.W., The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 10 (2009), 561–572.
26. Wolf, M.E., Synaptic mechanisms underlying persistent cocaine craving. Nat Rev Neurosci 17 (2016), 351–365.
27. Shalev, U., Grimm, J.W., Shaham, Y., Neurobiology of relapse to heroin and cocaine seeking: A review. Pharmacol Rev 54 (2002), 1–42.
28. Acri, J.B., Cross, A.J., Skolnick, P., From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders. Psychopharmacology (Berl) 234 (2017), 1347–1355.
29. Goodwani, S., Saternos, H., Alasmari, F., Sari, Y., Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder. Neurosci Biobehav Rev 77 (2017), 14–31.
30. Luscher, C., Drug-evoked synaptic plasticity causing addictive behavior. J Neurosci 33 (2013), 17641–17646.
31. Bowers, M.S., Chen, B.T., Bonci, A., AMPA receptor synaptic plasticity induced by psychostimulants: The past, present, and therapeutic future. Neuron 67 (2010), 11–24.
32. Engers, D.W., Lindsley, C.W., Allosteric modulation of Class C GPCRs: A novel approach for the treatment of CNS disorders. Drug Discov Today Technol 10 (2013), e269–e276.
33. Hellyer, S., Leach, K., Gregory, K.J., Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation. Curr Opin Pharmacol 32 (2017), 49–55.
34. Conn, P.J., Christopoulos, A., Lindsley, C.W., Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8 (2009), 41–54.
35. Conn, P.J., Lindsley, C.W., Meiler, J., Niswender, C.M., Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov 13 (2014), 692–708.
36. Sanger, H., Hanna, L., Colvin, E.M., Grubisha, O., Ursu, D., Heinz, B.A., et al. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR. Neuropharmacology 66 (2013), 264–273.
37. Hermans, E., Challiss, R.A., Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: Prototypic family C G-protein-coupled receptors. Biochem J 359 (2001), 465–484.
38. Shigemoto, R., Nomura, S., Ohishi, H., Sugihara, H., Nakanishi, S., Mizuno, N., Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 163 (1993), 53–57.
39. Olive, M.F., Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. Eur J Pharmacol 639 (2010), 47–58.
40. Mihov, Y., Hasler, G., Negative allosteric modulators of metabotropic glutamate receptors subtype 5 in addiction: A therapeutic window. Int J Neuropsychopharmacol, 19, 2016.
41. Lavreysen, H., Wouters, R., Bischoff, F., Nobrega Pereira, S., Langlois, X., Blokland, S., et al. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 47 (2004), 961–972.
42. Penn, P.E., McBride, W.J., Lumeng, L., Gaff, T.M., Li, T.K., Neurochemical and operant behavioral studies of a strain of alcohol-preferring rats. Pharmacol Biochem Behav 8 (1978), 475–481.
43. Besheer, J., Faccidomo, S., Grondin, J.J., Hodge, C.W., Regulation of motivation to self-administer ethanol by mGluR5 in alcohol-preferring (P) rats. Alcohol Clin Exp Res 32 (2008), 209–221.
44. Besheer, J., Faccidomo, S., Grondin, J.J., Hodge, C.W., Effects of mGlu1-receptor blockade on ethanol self-administration in inbred alcohol-preferring rats. Alcohol 42 (2008), 13–20.
45. Schroeder, J.P., Overstreet, D.H., Hodge, C.W., The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats. Psychopharmacology (Berl) 179 (2005), 262–270.
46. Hodge, C.W., Miles, M.F., Sharko, A.C., Stevenson, R.A., Hillmann, J.R., Lepoutre, V., et al. The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice. Psychopharmacology (Berl) 183 (2006), 429–438.
47. Casabona, G., Knopfel, T., Kuhn, R., Gasparini, F., Baumann, P., Sortino, M.A., et al. Expression and coupling to polyphosphoinositide hydrolysis of group I metabotropic glutamate receptors in early postnatal and adult rat brain. Eur J Neurosci 9 (1997), 12–17.
48. Lominac, K.D., Kapasova, Z., Hannun, R.A., Patterson, C., Middaugh, L.D., Szumlinski, K.K., Behavioral and neurochemical interactions between Group 1 mGluR antagonists and ethanol: Potential insight into their anti-addictive properties. Drug Alcohol Depend 85 (2006), 142–156.
49. Achat-Mendes, C., Platt, D.M., Spealman, R.D., Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys. J Pharmacol Exp Ther 343 (2012), 214–224.
50. Xie, X., Lasseter, H.C., Ramirez, D.R., Ponds, K.L., Wells, A.M., Fuchs, R.A., Subregion-specific role of glutamate receptors in the nucleus accumbens on drug context-induced reinstatement of cocaine-seeking behavior in rats. Addict Biol 17 (2012), 287–299.
51. Xie, X., Ramirez, D.R., Lasseter, H.C., Fuchs, R.A., Effects of mGluR1 antagonism in the dorsal hippocampus on drug context-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology (Berl) 208 (2010), 1–11.
52. Kohara, A., Toya, T., Tamura, S., Watabiki, T., Nagakura, Y., Shitaka, Y., et al. Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1. J Pharmacol Exp Ther 315 (2005), 163–169.
53. Schmidt, H.D., Kimmey, B.A., Arreola, A.C., Pierce, R.C., Group I metabotropic glutamate receptor-mediated activation of PKC gamma in the nucleus accumbens core promotes the reinstatement of cocaine seeking. Addict Biol 20 (2015), 285–296.
54. Lesage, A.S.J., Bischoff, F., Van Beijsterveldt, L., Meert, T., Steckler, T., Ashton, D., Novel, centrally active mGlu1 antagonists: In vitro and in vivo pharmacology. Neuropharmacology, 43, 2002 295–295.
55. Dravolina, O.A., Zakharova, E.S., Shekunova, E.V., Zvartau, E.E., Danysz, W., Bespalov, A.Y., mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology 52 (2007), 263–269.
56. Ngomba, R.T., Santolini, I., Biagioni, F., Molinaro, G., Simonyi, A., van Rijn, C.M., et al. Protective role for type-1 metabotropic glutamate receptors against spike and wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology 60 (2011), 1281–1291.
57. Loweth, J.A., Scheyer, A.F., Milovanovic, M., LaCrosse, A.L., Flores-Barrera, E., Werner, C.T., et al. Synaptic depression via mGluR1 positive allosteric modulation suppresses cue-induced cocaine craving. Nat Neurosci 17 (2014), 73–80.
58. Scheyer, A.F., Loweth, J.A., Christian, D.T., Uejima, J., Rabei, R., Le, T., et al. AMPA receptor plasticity in accumbens core contributes to incubation of methamphetamine craving. Biol Psychiatry 80 (2016), 661–670.
59. Halbout, B., Bernardi, R.E., Hansson, A.C., Spanagel, R., Incubation of cocaine seeking following brief cocaine experience in mice is enhanced by mGluR1 blockade. J Neurosci 34 (2014), 1781–1790.
60. El-Kouhen, O., Lehto, S.G., Pan, J.B., Chang, R., Baker, S.J., Zhong, C., et al. Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: Effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br J Pharmacol 149 (2006), 761–774.
61. Ben-Shahar, O., Sacramento, A.D., Miller, B.W., Webb, S.M., Wroten, M.G., Silva, H.E., et al. Deficits in ventromedial prefrontal cortex group 1 metabotropic glutamate receptor function mediate resistance to extinction during protracted withdrawal from an extensive history of cocaine self-administration. J Neurosci 33 (2013), 495–506a.
62. Fuchs, R.A., Branham, R.K., See, R.E., Different neural substrates mediate cocaine seeking after abstinence versus extinction training: A critical role for the dorsolateral caudate-putamen. J Neurosci 26 (2006), 3584–3588.
63. Marchant, N.J., Li, X., Shaham, Y., Recent developments in animal models of drug relapse. Curr Opin Neurobiol 23 (2013), 675–683.
64. Chiamulera, C., Epping-Jordan, M.P., Zocchi, A., Marcon, C., Cottiny, C., Tacconi, S., et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4 (2001), 873–874.
65. Gasparini, F., Lingenhohl, K., Stoehr, N., Flor, P.J., Heinrich, M., Vranesic, I., et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38 (1999), 1493–1503.
66. Anderson, J.J., Rao, S.P., Rowe, B., Giracello, D.R., Holtz, G., Chapman, D.F., et al. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: In vitro and in vivo characterization. J Pharmacol Exp Ther 303 (2002), 1044–1051.
67. Keck, T.M., Yang, H.J., Bi, G.H., Huang, Y., Zhang, H.Y., Srivastava, R., et al. Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: Implications for addiction treatment in humans. Psychopharmacology (Berl) 229 (2013), 253–265.
68. Lindsley, C.W., Emmitte, K.A., Recent progress in the discovery and development of negative allosteric modulators of mGluR5. Curr Opin Drug Discov Devel 12 (2009), 446–457.
69. Amato, R.J., Felts, A.S., Rodriguez, A.L., Venable, D.F., Morrison, R.D., Byers, F.W., et al. Substituted 1-phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: Discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction. ACS Chem Neurosci 4 (2013), 1217–1228.
70. Yokel, R.A., Intravenous self-administration: Response rates, the effects of pharmacological challenges, and drug preference. Bozarth, M.A., (eds.) Methods of Assessing the Reinforcing Properties of Abused Drugs, 1987, Springer-Verlag, New York, 1–34.
71. Sanger, D.J., Blackman, D.E., Rate-dependent effects of drugs: A review of the literature. Pharmacol Biochem Behav 4 (1976), 73–83.
72. Keck, T.M., Zou, M.F., Bi, G.H., Zhang, H.Y., Wang, X.F., Yang, H.J., et al. A novel mGluR5 antagonist, MFZ 10-7, inhibits cocaine-taking and cocaine-seeking behavior in rats. Addict Biol 19 (2014), 195–209.
73. Keck, T.M., Zou, M.F., Zhang, P., Rutledge, R.P., Newman, A.H., Metabotropic glutamate receptor 5 negative allosteric modulators as novel tools for in vivo investigation. ACS Med Chem Lett 3 (2012), 544–549.
74. Wu, W.N., McKown, L.A., O'Neill, P.J., In vitro and in vivo metabolism of the antianxiolytic agent fenobam in the rat. J Pharm Sci 84 (1995), 185–189.
75. Porter, R.H., Jaeschke, G., Spooren, W., Ballard, T.M., Buttelmann, B., Kolczewski, S., et al. Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315 (2005), 711–721.
76. Martinez, L.A., Gross, K.S., Himmler, B.T., Emmitt, N.L., Peterson, B.M., Zlebnik, N.E., et al. Estradiol facilitation of cocaine self-administration in female rats requires activation of mGluR5. eNeuro, 3, 2016.
77. Lindsley, C.W., Wisnoski, D.D., Leister, W.H., O'Brien, J.A., Lemaire, W., Williams, D.L. Jr., et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem 47 (2004), 5825–5828.
78. Movsesyan, V.A., O'Leary, D.M., Fan, L., Bao, W., Mullins, P.G., Knoblach, S.M., et al. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 296 (2001), 41–47.
79. Mathiesen, J.M., Svendsen, N., Brauner-Osborne, H., Thomsen, C., Ramirez, M.T., Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138 (2003), 1026–1030.
80. Heidbreder, C.A., Bianchi, M., Lacroix, L.P., Faedo, S., Perdona, E., Remelli, R., et al. Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse 50 (2003), 269–276.
81. Gass, J.T., Trantham-Davidson, H., Kassab, A.S., Glen, W.B. Jr., Olive, M.F., Chandler, L.J., Enhancement of extinction learning attenuates ethanol-seeking behavior and alters plasticity in the prefrontal cortex. J Neurosci 34 (2014), 7562–7574.
82. Perry, C.J., Reed, F., Zbukvic, I.C., Kim, J.H., Lawrence, A.J., The metabotropic glutamate 5 receptor is necessary for extinction of cocaine-associated cues. Br J Pharmacol 173 (2016), 1085–1094.
83. Kufahl, P.R., Hood, L.E., Nemirovsky, N.E., Barabas, P., Halstengard, C., Villa, A., et al. Positive Allosteric modulation of mGluR5 accelerates extinction learning but not relearning following methamphetamine self-administration. Front Pharmacol, 3, 2012, 194.
84. Widholm, J.J., Gass, J.T., Cleva, R.M., Olive, M.F., The mGluR5 positive allosteric modulator CDPPB does not alter extinction or contextual reinstatement of methamphetamine-seeking behavior in rats. J Addict Res Ther, 2011, S1.
85. Gregory, K.J., Herman, E.J., Ramsey, A.J., Hammond, A.S., Byun, N.E., Stauffer, S.R., et al. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. J Pharmacol Exp Ther 347 (2013), 438–457.
86. Peters, J., Scofield, M.D., Ghee, S.M., Heinsbroek, J.A., Reichel, C.M., Perirhinal cortex mGlu5 receptor activation reduces relapse to methamphetamine seeking by restoring novelty salience. Neuropsychopharmacology 41 (2016), 1477–1485.
87. See, R.E., Neural substrates of conditioned-cued relapse to drug-seeking behavior. Pharmacol Biochem Behav 71 (2002), 517–529.
88. Watterson, L.R., Kufahl, P.R., Nemirovsky, N.E., Sewalia, K., Hood, L.E., Olive, M.F., Attenuation of reinstatement of methamphetamine-, sucrose-, and food-seeking behavior in rats by fenobam, a metabotropic glutamate receptor 5 negative allosteric modulator. Psychopharmacology (Berl) 225 (2013), 151–159.
89. Olive, M.F., Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug Abuse Rev 2 (2009), 83–98.
90. Paterson, N.E., Markou, A., The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology (Berl) 179 (2005), 255–261.
91. Bossert, J.M., Marchant, N.J., Calu, D.J., Shaham, Y., The reinstatement model of drug relapse: Recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology (Berl) 229 (2013), 453–476.
92. Li, X., Caprioli, D., Marchant, N.J., Recent updates on incubation of drug craving: a mini-review. Addict Biol 20 (2015), 872–876.
93. Li, X., Zeric, T., Kambhampati, S., Bossert, J.M., Shaham, Y., The central amygdala nucleus is critical for incubation of methamphetamine craving. Neuropsychopharmacology 40 (2015), 1297–1306.
94. Schoepp, D.D., Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299 (2001), 12–20.
95. Tamaru, Y., Nomura, S., Mizuno, N., Shigemoto, R., Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites. Neuroscience 106 (2001), 481–503.
96. Ohishi, H., Shigemoto, R., Nakanishi, S., Mizuno, N., Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 53 (1993), 1009–1018.
97. Xi, Z.X., Ramamoorthy, S., Baker, D.A., Shen, H., Samuvel, D.J., Kalivas, P.W., Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J Pharmacol Exp Ther 303 (2002), 608–615.
98. Anwyl, R., Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity. Brain Res Rev 29 (1999), 83–120.
99. Monn, J.A., Valli, M.J., Massey, S.M., Hansen, M.M., Kress, T.J., Wepsiec, J.P., et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42 (1999), 1027–1040.
100. Rodd, Z.A., McKinzie, D.L., Bell, R.L., McQueen, V.K., Murphy, J.M., Schoepp, D.D., et al. The metabotropic glutamate 2/3 receptor agonist LY404039 reduces alcohol-seeking but not alcohol self-administration in alcohol-preferring (P) rats. Behav Brain Res 171 (2006), 207–215.
101. Bossert, J.M., Liu, S.Y., Lu, L., Shaham, Y., A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking. J Neurosci 24 (2004), 10726–10730.
102. Bossert, J.M., Poles, G.C., Sheffler-Collins, S.I., Ghitza, U.E., The mGluR2/3 agonist LY379268 attenuates context- and discrete cue-induced reinstatement of sucrose seeking but not sucrose self-administration in rats. Behav Brain Res 173 (2006), 148–152.
103. Baptista, M.A., Martin-Fardon, R., Weiss, F., Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: Comparison between cocaine and a potent conventional reinforcer. J Neurosci 24 (2004), 4723–4727.
104. Kufahl, P.R., Watterson, L.R., Nemirovsky, N.E., Hood, L.E., Villa, A., Halstengard, C., et al. Attenuation of methamphetamine seeking by the mGluR2/3 agonist LY379268 in rats with histories of restricted and escalated self-administration. Neuropharmacology 66 (2013), 290–301.
105. Adewale, A.S., Platt, D.M., Spealman, R.D., Pharmacological stimulation of group II metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys. J Pharmacol Exp Ther 318 (2006), 922–931.
106. Justinova, Z., Le Foll, B., Redhi, G.H., Markou, A., Goldberg, S.R., Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys. Psychopharmacology (Berl) 233 (2016), 1791–1800.
107. Liechti, M.E., Lhuillier, L., Kaupmann, K., Markou, A., Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci 27 (2007), 9077–9085.
108. Crawford, J.T., Roberts, D.C., Beveridge, T.J., The group II metabotropic glutamate receptor agonist, LY379268, decreases methamphetamine self-administration in rats. Drug Alcohol Depend 132 (2013), 414–419.
109. Lu, L., Uejima, J.L., Gray, S.M., Bossert, J.M., Shaham, Y., Systemic and central amygdala injections of the mGluR(2/3) agonist LY379268 attenuate the expression of incubation of cocaine craving. Biol Psychiatry 61 (2007), 591–598.
110. Jin, X., Semenova, S., Yang, L., Ardecky, R., Sheffler, D.J., Dahl, R., et al. The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats. Neuropsychopharmacology 35 (2010), 2021–2036.
111. Galici, R., Jones, C.K., Hemstapat, K., Nong, Y., Echemendia, N.G., Williams, L.C., et al. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318 (2006), 173–185.
112. Dhanya, R.P., Sidique, S., Sheffler, D.J., Nickols, H.H., Herath, A., Yang, L., et al. Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem 54 (2011), 342–353.
113. Sidique, S., Dhanya, R.P., Sheffler, D.J., Nickols, H.H., Yang, L., Dahl, R., et al. Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: Structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem 55 (2012), 9434–9445.
114. Dhanya, R.P., Sheffler, D.J., Dahl, R., Davis, M., Lee, P.S., Yang, L., et al. Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): Pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem 57 (2014), 4154–4172.
115. Cross AJ (2013): AZD8529—an mGluR2 positive allosteric modulator for the treatment of schizophrenia. Presented at the American College of Neuropsychopharmacology Annual Meeting, December 8–12, Hollywood, Florida.
116. Justinova, Z., Panlilio, L.V., Secci, M.E., Redhi, G.H., Schindler, C.W., Cross, A.J., et al. The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys. Biol Psychiatry 78 (2015), 452–462.
117. Li, X., D'Souza, M.S., Nino, A.M., Doherty, J., Cross, A., Markou, A., Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats. Psychopharmacology (Berl) 233 (2016), 1801–1814.
118. Augier, E., Dulman, R.S., Rauffenbart, C., Augier, G., Cross, A.J., Heilig, M., The mGluR2 positive allosteric modulator, AZD8529, and cue-induced relapse to alcohol seeking in rats. Neuropsychopharmacology 41 (2016), 2932–2940.
119. Zhou, Z., Karlsson, C., Liang, T., Xiong, W., Kimura, M., Tapocik, J.D., et al. Loss of metabotropic glutamate receptor 2 escalates alcohol consumption. Proc Natl Acad Sci U S A 110 (2013), 16963–16968.
120. Caprioli, D., Venniro, M., Zeric, T., Li, X., Adhikary, S., Madangopal, R., et al. Effect of the novel positive allosteric modulator of metabotropic glutamate receptor 2 AZD8529 on incubation of methamphetamine craving after prolonged voluntary abstinence in a rat model. Biol Psychiatry 78 (2015), 463–473.
121. Caprioli, D., Venniro, M., Zhang, M., Bossert, J.M., Warren, B.L., Hope, B.T., et al. Role of dorsomedial striatum neuronal ensembles in incubation of methamphetamine craving after voluntary abstinence. J Neurosci 37 (2017), 1014–1027.
122. Venniro, M., Zhang, M., Shaham, Y., Caprioli, D., Incubation of methamphetamine but not heroin craving after voluntary abstinence in male and female rats. Neuropsychopharmacology 42 (2017), 1126–1135.
123. Venniro, M., Caprioli, D., Zhang, M., Whitaker, L.R., Zhang, S., Warren, B.L., et al. The anterior insular cortex→central amygdala glutamatergic pathway is critical to relapse after contingency management. Neuron 96 (2017), 414–427.
124. Conn, P.J., Pin, J.P., Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37 (1997), 205–237.
125. Kinzie, J.M., Saugstad, J.A., Westbrook, G.L., Segerson, T.P., Distribution of metabotropic glutamate receptor 7 messenger RNA in the developing and adult rat brain. Neuroscience 69 (1995), 167–176.
126. Corti, C., Aldegheri, L., Somogyi, P., Ferraguti, F., Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. Neuroscience 110 (2002), 403–420.
127. Nakajima, Y., Iwakabe, H., Akazawa, C., Nawa, H., Shigemoto, R., Mizuno, N., et al. Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J Biol Chem 268 (1993), 11868–11873.
128. Sheardown, M.J., A new and specific non-NMDA receptor antagonist, FG 9065, blocks L-AP4-evoked depolarization in rat cerebral cortex. Eur J Pharmacol 148 (1988), 471–474.
129. Schoepp, D.D., Jane, D.E., Monn, J.A., Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38 (1999), 1431–1476.
130. Mao, L., Guo, M., Jin, D., Xue, B., Wang, J.Q., Group III metabotropic glutamate receptors and drug addiction. Front Med 7 (2013), 445–451.
131. Mitsukawa, K., Yamamoto, R., Ofner, S., Nozulak, J., Pescott, O., Lukic, S., et al. A selective metabotropic glutamate receptor 7 agonist: Activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci U S A 102 (2005), 18712–18717.
132. Salling, M.C., Faccidomo, S., Hodge, C.W., Nonselective suppression of operant ethanol and sucrose self-administration by the mGluR7 positive allosteric modulator AMN082. Pharmacol Biochem Behav 91 (2008), 14–20.
133. Li, X., Li, J., Peng, X.Q., Spiller, K., Gardner, E.L., Xi, Z.X., Metabotropic glutamate receptor 7 modulates the rewarding effects of cocaine in rats: Involvement of a ventral pallidal GABAergic mechanism. Neuropsychopharmacology 34 (2009), 1783–1796.
134. Suzuki, G., Tsukamoto, N., Fushiki, H., Kawagishi, A., Nakamura, M., Kurihara, H., et al. In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists. J Pharmacol Exp Ther 323 (2007), 147–156.
135. Li, X., Li, J., Gardner, E.L., Xi, Z.X., Activation of mGluR7s inhibits cocaine-induced reinstatement of drug-seeking behavior by a nucleus accumbens glutamate-mGluR2/3 mechanism in rats. J Neurochem 114 (2010), 1368–1380.
136. Pierce, R.C., O'Brien, C.P., Kenny, P.J., Vanderschuren, L.J., Rational development of addiction pharmacotherapies: Successes, failures, and prospects. Cold Spring Harb Perspect Med, 2, 2012, a012880.
137. Schmidt, H.D., Pierce, R.C., Cocaine-induced neuroadaptations in glutamate transmission: Potential therapeutic targets for craving and addiction. Ann N Y Acad Sci 1187 (2010), 35–75.
138. Pickens, C.L., Airavaara, M., Theberge, F., Fanous, S., Hope, B.T., Shaham, Y., Neurobiology of the incubation of drug craving. Trends Neurosci 34 (2011), 411–420.
139. Wootten, D., Christopoulos, A., Sexton, P.M., Emerging paradigms in GPCR allostery: Implications for drug discovery. Nat Rev Drug Discov 12 (2013), 630–644.
140. Marlatt, G.A., Cue exposure and relapse prevention in the treatment of addictive behaviors. Addict Behav 15 (1990), 395–399.
141. Bouton, M.E., Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction. Biol Psychiatry 52 (2002), 976–986.
142. Conklin, C.A., Tiffany, S.T., Applying extinction research and theory to cue-exposure addiction treatments. Addiction 97 (2002), 155–167.
143. Heilig, M., Epstein, D.H., Nader, M.A., Shaham, Y., Time to connect: Bringing social context into addiction neuroscience. Nat Rev Neurosci 17 (2016), 592–599.
144. Mantsch, J.R., Baker, D.A., Funk, D., Le, A.D., Shaham, Y., Stress-induced reinstatement of drug seeking: 20 years of progress. Neuropsychopharmacology 41 (2016), 335–356.
145. LaRowe, S.D., Kalivas, P.W., Nicholas, J.S., Randall, P.K., Mardikian, P.N., Malcolm, R.J., A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict 22 (2013), 443–452.
146. Kwako, L.E., Spagnolo, P.A., Schwandt, M.L., Thorsell, A., George, D.T., Momenan, R., et al. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: A randomized controlled experimental medicine study. Neuropsychopharmacology 40 (2015), 1053–1063.
147. Schwandt, M.L., Cortes, C.R., Kwako, L.E., George, D.T., Momenan, R., Sinha, R., et al. The CRF1 antagonist verucerfont in anxious alcohol-dependent women: Translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacology 41 (2016), 2818–2829.
148. Vendruscolo, L.F., Estey, D., Goodell, V., Macshane, L.G., Logrip, M.L., Schlosburg, J.E., et al. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest 125 (2015), 3193–3197.
149. Kowalczyk, W.J., Phillips, K.A., Jobes, M.L., Kennedy, A.P., Ghitza, U.E., Agage, D.A., et al. Clonidine maintenance prolongs opioid abstinence and decouples stress from craving in daily life: A randomized controlled trial with ecological momentary assessment. Am J Psychiatry 172 (2015), 760–767.
150. Shaham, Y., de Wit, H., Lost in translation: CRF1 receptor antagonists and addiction treatment. Neuropsychopharmacology 41 (2016), 2795–2797.